Biotechnology News and Research RSS Feed - Biotechnology News and Research

Can-Fite BioPharma begins dosing in CF102 Phase II liver cancer trial

Can-Fite BioPharma begins dosing in CF102 Phase II liver cancer trial

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced that it has dosed the first patient in a Phase II trial for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. [More]
Oncolytics Biotech submits Orphan Designation to EMA for treatment of ovarian, pancreatic cancers

Oncolytics Biotech submits Orphan Designation to EMA for treatment of ovarian, pancreatic cancers

Oncolytics Biotech Inc. ("Oncolytics") today announced that it has submitted applications for Orphan Designation to the European Medicines Agency ("EMA") for REOLYSIN® for the treatment of pancreatic and ovarian cancers. [More]
Study explores prevalence of Internet addiction and its effect on quality of life

Study explores prevalence of Internet addiction and its effect on quality of life

Internet addiction is an impulse-control problem marked by an inability to inhibit Internet use, which can adversely affect a person's life, including their health and interpersonal relationships. [More]
C3BS enrols 240th patient in CHART-1 European trial of C-Cure for treatment of congestive heart failure

C3BS enrols 240th patient in CHART-1 European trial of C-Cure for treatment of congestive heart failure

Cardio3 BioSciences, a leader in the discovery and development of regenerative, protective and reconstructive therapies, announces today the enrolment of the 240th patient in its CHART-1 European trial for C-Cure, the first and only stem cell therapeutic using guided stem cells for the treatment of congestive heart failure. [More]
Lilly, Adocia team up to develop BioChaperone Lispro insulin for treatment of diabetes

Lilly, Adocia team up to develop BioChaperone Lispro insulin for treatment of diabetes

Eli Lilly and Company and Adocia today announced a worldwide licensing collaboration focused on developing an ultra-rapid insulin, known as BioChaperone Lispro, for treatment in people with type 1 and type 2 diabetes. [More]
Researchers treat myocardial infarction with new telomerase-based gene therapy

Researchers treat myocardial infarction with new telomerase-based gene therapy

The enzyme telomerase repairs cell damage produced by ageing, and has been used successfully in therapies to lengthen the life of mice. Now it has been observed that it could also be used to cure illnesses related to the ageing process. [More]
Study offers insights into mechanisms of bacterial resistance to antimicrobial peptides

Study offers insights into mechanisms of bacterial resistance to antimicrobial peptides

Antimicrobial peptides are a distinctive class of potent, broad-spectrum antibiotics produced by the body's innate immune system--the first line of defense against disease-causing microbes. [More]
New study finds high suicide rates among transgender veterans

New study finds high suicide rates among transgender veterans

Veterans of the U.S. armed forces who have received a diagnosis consistent with transgender status are more likely to have serious suicidal thoughts and plans and to attempt suicide. [More]
Scientists discover how certain gut bacteria can protect themselves, others from antibiotics

Scientists discover how certain gut bacteria can protect themselves, others from antibiotics

Scientists from the Institute of Food Research and the University of East Anglia have discovered how certain gut bacteria can protect themselves and others in the gut from antibiotics. [More]
UK doctors to test cannabis-based medicine for children with severe epilepsy

UK doctors to test cannabis-based medicine for children with severe epilepsy

Children with severe epilepsy could be helped by a new treatment derived from the cannabis plant. [More]
Novel technique to identify biological markers in brain development

Novel technique to identify biological markers in brain development

With a unique, multi-faceted approach, researchers at the Lieber Institute for Brain Development have quantified the effect of previously unidentified anomalies in genetic expression that determine how the human brain develops from its earliest stages. [More]
New study shows that people may inherit intestinal bacteria that cause inflammatory bowel disease

New study shows that people may inherit intestinal bacteria that cause inflammatory bowel disease

A new study by an international team of researchers shows for the first time that people may inherit some of the intestinal bacteria that cause Crohn's disease and ulcerative colitis, collectively know as inflammatory bowel disease (IBD). The study, recently published in Genome Medicine, also confirmed that antibiotics could worsen the imbalance in the gut microbes. [More]
Pre-clinical studies confirm TRXE-009 as new potential treatment for melanoma

Pre-clinical studies confirm TRXE-009 as new potential treatment for melanoma

Novogen Limited, Australian/US biotechnology company, today announces that it has confirmed that its lead candidate product, TRXE-009, originally developed for the treatment of brain cancers, has been shown in pre-clinical studies also to be highly active against melanoma. [More]
VirtualScopics signs software licence, support agreement with IXICO

VirtualScopics signs software licence, support agreement with IXICO

VirtualScopics, Inc., a leading provider of clinical trial imaging solutions, today announced that they have signed a multi-year software licence and support agreement with existing alliance partner, IXICO plc, the brain health company, for their proprietary imaging data and query management digital platform, TrialTracker™. [More]
ANTRUK welcomes first report on antibiotic resistance; becomes BIA’s 2015 charity

ANTRUK welcomes first report on antibiotic resistance; becomes BIA’s 2015 charity

Professor Colin Garner, Chief Executive of Antibiotic Research UK (ANTRUK), the world’s first charity to tackle the impending health disaster of antibiotic resistance, welcomed the publication of the first report by the O’Neill Commission on antibiotic resistance. [More]
TWi Biotechnology gets approval of Phase II clinical trial protocol for AC-201 CR tablets

TWi Biotechnology gets approval of Phase II clinical trial protocol for AC-201 CR tablets

TWi Pharmaceuticals, Inc. today announced that its fully owned subsidiary, TWi Biotechnology, Inc., has received US FDA and Taiwan FDA approval of a protocol for a Phase II clinical trial of its AC-201 controlled-release (CR) tablets for the indications of high blood uric acid level and gout. [More]
New study compares usefulness of two biomarkers released into the blood after TBI

New study compares usefulness of two biomarkers released into the blood after TBI

In cases of traumatic brain injury (TBI), predicting the likelihood of a cranial lesion and determining the need for head computed tomography (CT) can be aided by measuring markers of bone injury in the blood. [More]
Experiments to probe bacteria virulence in low gravity of space station

Experiments to probe bacteria virulence in low gravity of space station

The University of Colorado Boulder will fly state-of-the-art hardware on the commercial SpaceX Dragon spacecraft launching to the International Space Station Dec. 19 to support experiments designed to better understand why the virulence of some pathogens increases in the low gravity of space. [More]
Leica Biosystems, Mayo Clinic partner to develop next generation of cytogenetics imaging software

Leica Biosystems, Mayo Clinic partner to develop next generation of cytogenetics imaging software

Leica Biosystems and Mayo Clinic's Department of Laboratory Medicine and Pathology announced today a collaboration to develop the next generation of cytogenetics imaging software. The new tool will optimize software workflow and improve the overall user experience for cytogenetics imaging technicians. [More]
Champions reports decrease in revenue for second quarter of 2015

Champions reports decrease in revenue for second quarter of 2015

Champions Oncology, Inc., engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the second quarter ended October 31, 2014. [More]